Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors

Natalie J. Engmann, Christopher G. Scott, Matthew R. Jensen, Lin Ma, Kathleen R Brandt, Amir Pasha Mahmoudzadeh, Serghei Malkov, Dana H. Whaley, Carrie B Hruska, Fang Fang Wu, Stacey J Winham, Diana L. Miglioretti, Aaron D. Norman, John J. Heine, John Shepherd, V. Shane Pankratz, Celine M Vachon, Karla Kerlikowske

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Reductions in breast density with tamoxifen and aromatase inhibitors may be an intermediate marker of treatment response. We compare changes in volumetric breast density among breast cancer cases using tamoxifen or aromatase inhibitors (AI) to untreated women without breast cancer. Methods: Breast cancer cases with a digital mammogram prior to diagnosis and after initiation of tamoxifen (n= 366) or AI (n= 403) and a sample of controls (n=2170) were identified from the Mayo Clinic Mammography Practice and San Francisco Mammography Registry. Volumetric percent density (VPD) and dense breast volume (DV) were measured using Volpara (Matakina Technology) and Quantra (Hologic) software. Linear regression estimated the effect of treatment on annualized changes in density. Results: Premenopausal women using tamoxifen experienced annualized declines in VPD of 1.17% to 1.70% compared with 0.30% to 0.56% for controls and declines in DV of 7.43 to 15.13 cm3 compared with 0.28 to 0.63 cm3 in controls, for Volpara and Quantra, respectively. The greatest reductions were observed among women with 10% baseline density. Postmenopausal AI users had greater declines in VPD than controls (Volpara P = 0.02; Quantra P = 0.03), and reductions were greatest among women with 10% baseline density. Declines in VPD among postmenopausal women using tamoxifen were only statistically greater than controls when measured with Quantra. Conclusions: Automated software can detect volumetric breast density changes among women on tamoxifen and AI. Impact: If declines in volumetric density predict breast cancer outcomes, these measures may be used as interim prognostic indicators.

Original languageEnglish (US)
Pages (from-to)930-937
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Aromatase Inhibitors
Tamoxifen
Breast Neoplasms
Mammography
Software
San Francisco
Registries
Breast Density
Linear Models
Breast
Outcome Assessment (Health Care)
Technology
Therapeutics

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. / Engmann, Natalie J.; Scott, Christopher G.; Jensen, Matthew R.; Ma, Lin; Brandt, Kathleen R; Mahmoudzadeh, Amir Pasha; Malkov, Serghei; Whaley, Dana H.; Hruska, Carrie B; Wu, Fang Fang; Winham, Stacey J; Miglioretti, Diana L.; Norman, Aaron D.; Heine, John J.; Shepherd, John; Pankratz, V. Shane; Vachon, Celine M; Kerlikowske, Karla.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 26, No. 6, 01.06.2017, p. 930-937.

Research output: Contribution to journalArticle

Engmann, NJ, Scott, CG, Jensen, MR, Ma, L, Brandt, KR, Mahmoudzadeh, AP, Malkov, S, Whaley, DH, Hruska, CB, Wu, FF, Winham, SJ, Miglioretti, DL, Norman, AD, Heine, JJ, Shepherd, J, Pankratz, VS, Vachon, CM & Kerlikowske, K 2017, 'Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors', Cancer Epidemiology Biomarkers and Prevention, vol. 26, no. 6, pp. 930-937. https://doi.org/10.1158/1055-9965.EPI-16-0882
Engmann, Natalie J. ; Scott, Christopher G. ; Jensen, Matthew R. ; Ma, Lin ; Brandt, Kathleen R ; Mahmoudzadeh, Amir Pasha ; Malkov, Serghei ; Whaley, Dana H. ; Hruska, Carrie B ; Wu, Fang Fang ; Winham, Stacey J ; Miglioretti, Diana L. ; Norman, Aaron D. ; Heine, John J. ; Shepherd, John ; Pankratz, V. Shane ; Vachon, Celine M ; Kerlikowske, Karla. / Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors. In: Cancer Epidemiology Biomarkers and Prevention. 2017 ; Vol. 26, No. 6. pp. 930-937.
@article{afc6f8ca3f7e4a88829b77c36f24e804,
title = "Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors",
abstract = "Background: Reductions in breast density with tamoxifen and aromatase inhibitors may be an intermediate marker of treatment response. We compare changes in volumetric breast density among breast cancer cases using tamoxifen or aromatase inhibitors (AI) to untreated women without breast cancer. Methods: Breast cancer cases with a digital mammogram prior to diagnosis and after initiation of tamoxifen (n= 366) or AI (n= 403) and a sample of controls (n=2170) were identified from the Mayo Clinic Mammography Practice and San Francisco Mammography Registry. Volumetric percent density (VPD) and dense breast volume (DV) were measured using Volpara (Matakina Technology) and Quantra (Hologic) software. Linear regression estimated the effect of treatment on annualized changes in density. Results: Premenopausal women using tamoxifen experienced annualized declines in VPD of 1.17{\%} to 1.70{\%} compared with 0.30{\%} to 0.56{\%} for controls and declines in DV of 7.43 to 15.13 cm3 compared with 0.28 to 0.63 cm3 in controls, for Volpara and Quantra, respectively. The greatest reductions were observed among women with 10{\%} baseline density. Postmenopausal AI users had greater declines in VPD than controls (Volpara P = 0.02; Quantra P = 0.03), and reductions were greatest among women with 10{\%} baseline density. Declines in VPD among postmenopausal women using tamoxifen were only statistically greater than controls when measured with Quantra. Conclusions: Automated software can detect volumetric breast density changes among women on tamoxifen and AI. Impact: If declines in volumetric density predict breast cancer outcomes, these measures may be used as interim prognostic indicators.",
author = "Engmann, {Natalie J.} and Scott, {Christopher G.} and Jensen, {Matthew R.} and Lin Ma and Brandt, {Kathleen R} and Mahmoudzadeh, {Amir Pasha} and Serghei Malkov and Whaley, {Dana H.} and Hruska, {Carrie B} and Wu, {Fang Fang} and Winham, {Stacey J} and Miglioretti, {Diana L.} and Norman, {Aaron D.} and Heine, {John J.} and John Shepherd and Pankratz, {V. Shane} and Vachon, {Celine M} and Karla Kerlikowske",
year = "2017",
month = "6",
day = "1",
doi = "10.1158/1055-9965.EPI-16-0882",
language = "English (US)",
volume = "26",
pages = "930--937",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Longitudinal changes in volumetric breast density with tamoxifen and aromatase inhibitors

AU - Engmann, Natalie J.

AU - Scott, Christopher G.

AU - Jensen, Matthew R.

AU - Ma, Lin

AU - Brandt, Kathleen R

AU - Mahmoudzadeh, Amir Pasha

AU - Malkov, Serghei

AU - Whaley, Dana H.

AU - Hruska, Carrie B

AU - Wu, Fang Fang

AU - Winham, Stacey J

AU - Miglioretti, Diana L.

AU - Norman, Aaron D.

AU - Heine, John J.

AU - Shepherd, John

AU - Pankratz, V. Shane

AU - Vachon, Celine M

AU - Kerlikowske, Karla

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: Reductions in breast density with tamoxifen and aromatase inhibitors may be an intermediate marker of treatment response. We compare changes in volumetric breast density among breast cancer cases using tamoxifen or aromatase inhibitors (AI) to untreated women without breast cancer. Methods: Breast cancer cases with a digital mammogram prior to diagnosis and after initiation of tamoxifen (n= 366) or AI (n= 403) and a sample of controls (n=2170) were identified from the Mayo Clinic Mammography Practice and San Francisco Mammography Registry. Volumetric percent density (VPD) and dense breast volume (DV) were measured using Volpara (Matakina Technology) and Quantra (Hologic) software. Linear regression estimated the effect of treatment on annualized changes in density. Results: Premenopausal women using tamoxifen experienced annualized declines in VPD of 1.17% to 1.70% compared with 0.30% to 0.56% for controls and declines in DV of 7.43 to 15.13 cm3 compared with 0.28 to 0.63 cm3 in controls, for Volpara and Quantra, respectively. The greatest reductions were observed among women with 10% baseline density. Postmenopausal AI users had greater declines in VPD than controls (Volpara P = 0.02; Quantra P = 0.03), and reductions were greatest among women with 10% baseline density. Declines in VPD among postmenopausal women using tamoxifen were only statistically greater than controls when measured with Quantra. Conclusions: Automated software can detect volumetric breast density changes among women on tamoxifen and AI. Impact: If declines in volumetric density predict breast cancer outcomes, these measures may be used as interim prognostic indicators.

AB - Background: Reductions in breast density with tamoxifen and aromatase inhibitors may be an intermediate marker of treatment response. We compare changes in volumetric breast density among breast cancer cases using tamoxifen or aromatase inhibitors (AI) to untreated women without breast cancer. Methods: Breast cancer cases with a digital mammogram prior to diagnosis and after initiation of tamoxifen (n= 366) or AI (n= 403) and a sample of controls (n=2170) were identified from the Mayo Clinic Mammography Practice and San Francisco Mammography Registry. Volumetric percent density (VPD) and dense breast volume (DV) were measured using Volpara (Matakina Technology) and Quantra (Hologic) software. Linear regression estimated the effect of treatment on annualized changes in density. Results: Premenopausal women using tamoxifen experienced annualized declines in VPD of 1.17% to 1.70% compared with 0.30% to 0.56% for controls and declines in DV of 7.43 to 15.13 cm3 compared with 0.28 to 0.63 cm3 in controls, for Volpara and Quantra, respectively. The greatest reductions were observed among women with 10% baseline density. Postmenopausal AI users had greater declines in VPD than controls (Volpara P = 0.02; Quantra P = 0.03), and reductions were greatest among women with 10% baseline density. Declines in VPD among postmenopausal women using tamoxifen were only statistically greater than controls when measured with Quantra. Conclusions: Automated software can detect volumetric breast density changes among women on tamoxifen and AI. Impact: If declines in volumetric density predict breast cancer outcomes, these measures may be used as interim prognostic indicators.

UR - http://www.scopus.com/inward/record.url?scp=85020211770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020211770&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-16-0882

DO - 10.1158/1055-9965.EPI-16-0882

M3 - Article

VL - 26

SP - 930

EP - 937

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -